罗欣药业(002793) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 264,358,065.86, representing a year-on-year increase of 33.09%[8] - Net profit attributable to shareholders was a loss of CNY 1,716,566.53, a decline of 105.60% compared to the same period last year[8] - Basic earnings per share were -0.005 CNY, down 105.56% from the previous year[8] - The weighted average return on net assets was -0.18%, a decrease of 3.91% compared to the previous year[8] - Total operating revenue for Q3 2019 reached ¥264,358,065.86, an increase of 33.06% compared to ¥198,635,539.30 in Q3 2018[43] - Net profit for Q3 2019 was a loss of ¥1,716,566.53, compared to a profit of ¥30,675,139.43 in Q3 2018, indicating a significant decline in profitability[44] - The net profit for the third quarter was CNY 20,264,251, down 33.8% from CNY 30,613,415 in the previous year[48] - The total comprehensive income for the third quarter was CNY -1,733,624.41, compared to CNY 30,675,139.43 in the same period last year[46] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,360,226,330.93, a decrease of 2.96% compared to the previous year[8] - The company's current assets decreased to CNY 641,203,007.64 from CNY 817,228,372.03, indicating a decline of approximately 21.5%[34] - The cash and cash equivalents decreased to CNY 249,821,107.43 from CNY 323,353,063.94, representing a reduction of about 22.7%[33] - Accounts receivable fell to CNY 133,524,120.36 from CNY 165,919,151.81, a decrease of approximately 19.5%[33] - Inventory increased to CNY 237,203,980.95 from CNY 193,221,529.11, reflecting an increase of about 22.8%[33] - The company’s total liabilities decreased by 40.66% to ¥129,628,037 due to an increase in convertible bonds being converted into shares[17] - The company's total liabilities decreased to ¥332,455,233.76, down 33.19% from ¥497,623,020.21 in the previous year[40] - The total assets amounted to CNY 1,401,732,445.47, with total liabilities of CNY 491,846,210.54, resulting in total equity of CNY 909,886,234.93[69] Cash Flow - Net cash flow from operating activities improved to CNY 2,299,843.22, a significant increase of 221.81% year-on-year[8] - Cash flow from operating activities generated a net amount of ¥147,487,875.67, significantly higher than ¥44,224,551.02 in the previous period[59] - Net cash flow from operating activities was CNY 60,788,294.63, an increase of 38.0% compared to CNY 43,984,806.58 in the prior period[63] - Cash outflow from investing activities was CNY 151,638,261.42, compared to CNY 127,610,372.01 in the previous period, indicating a rise of 18.8%[63] - Net cash flow from investing activities was negative CNY 39,572,052.30, an improvement from negative CNY 115,511,046.97 in the prior period[63] - Financing activities resulted in a net cash outflow of ¥175,104,020.93, compared to a net inflow of ¥299,765,736.14 in the previous period[60] Shareholder Information - Net assets attributable to shareholders increased by 9.35% to CNY 995,005,872.03 compared to the previous year[8] - The total number of ordinary shareholders at the end of the reporting period was 19,741[12] - The largest shareholder, Fang Xiubao, holds 37.18% of the shares, with 100,016,262 shares pledged[13] Research and Development - Research and development expenses rose by 48.44% to ¥36,941,171, indicating increased investment in R&D activities[18] - Research and development expenses for Q3 2019 were ¥16,070,706.66, an increase of 82.00% from ¥8,814,911.20 in Q3 2018[43] - Research and development expenses increased to CNY 13,588,277.05, up 54.1% from CNY 8,814,911.20 in the previous year[46] Government Support - The company received government subsidies amounting to CNY 4,649,911.07 during the reporting period[11] Other Information - The company reported no violations regarding external guarantees or non-operating fund occupation during the reporting period[26][27] - There were no significant updates on new product development, market expansion, or mergers and acquisitions mentioned in the report[31] - The company has not undergone an audit for the third quarter report[76] - The report indicates a new financial instrument standard was implemented, affecting the classification of certain financial liabilities[75]